

Dear Editor:

We thank you very much for giving us an opportunity to revise our manuscript for possible publication in *World Journal of Gastroenterology*. We appreciate you and the reviewers very much for their thoughtful and constructive comments on our manuscript entitled “Genetic variant of Cyclooxygenase-2 in gastric cancer: more inflammation and susceptibility”. (Manuscript NO: 63362).

We have studied reviewer’s comments carefully and have made revision which marked in red in the paper. We would like to express our great appreciation to you and reviewers for reviewing and evaluating our manuscript. Looking forward to hearing from you.

Thanks for all the help.

With kind regards,

Corresponding author: Kaijuan Wang

E-mail: kjwang@163.com

Dear reviewers:

Thank you for your excellent and insightful series of comments. We have tried our best to revise our manuscript according to the comments which you raised, and the amendments are highlighted in red in the revised manuscript. We hope that the revision is acceptable and look forward to hearing from you.

Thank you very much.

Best regards,

Corresponding author: Kaijuan Wang

E-mail: kjwang@163.com

Reviewer 1

Q1. The authors should exhibit the expression data of COX-2 in gastric cancer, the data exacted from TCGA and oncomine could be used here.

Response: We appreciate your time and effort in reviewing this manuscript. Thanks for your suggestion. It is our neglect that the data extracted from genotypic tissue expression (GTEx) and The Cancer Genome Atlas (TCGA) database is not exhibited in this review. Due to the large number of data, we have presented it in supplementary material and have marked it red in the manuscript.

Q2. The pathways involved in COX-2 and cancer development should be summarized and presented in a separate figure.

Response: We appreciate your time and effort in reviewing this manuscript. Thanks for your advice. Indeed, it is more appropriate to summarize the inflammatory mechanism of COX-2 in gastric cancer in the diagram, which we have drawn and presented in figure 3.

Q3. If there were reports that were associated with clinical application of COX-2 inhibitor in preventing or treating cancer, the authors should summarize these studies and listed these studies in a separate table.

Response: We appreciate your time and effort in reviewing this manuscript. Thanks for your comment. The application of COX-2 inhibitors in tumor prevention and treatment has been a research hotspot because of its antitumor activity in cancer. In recent years, the combined application of COX-2 inhibitors and the development of new inhibitors have gradually emerged. We have summarized these studies and listed them in table 2.